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Abstract
Introduction. Immune-mediated angiogenesis may play an important role in the pathogenesis of inflammatory 
lesions in Crohn’s disease (CD). The study aimed to assess the influence of anti-tumour necrosis factor (anti-TNF) 
therapy on the angiogenesis in relation to microscopic and endoscopic healing in CD patients. 
Material and methods. Colonic tissue samples from 17 CD patients were taken during colonoscopy before and 
after anti-TNF therapy. Endoscopic and microscopic severities were estimated using validated scores. Immu-
nohistochemical expression of CD31 and vascular endothelial growth factor (VEGF) were assessed in parallel. 
Results. The expression of CD31 and VEGF decreased significantly after the anti-TNF therapy in parallel to 
endoscopic improvement; however, the microscopic activity did not change significantly. There was a correlation 
between the change in CD31 and VEGF expression (p = 0.01; r = 0.6), as well as endoscopic healing (p = 0.04; 
r = 0.4). CD31 immunoexpression correlated with the number of poly- and mononuclear cells in the infiltrates 
in the mucosal lamina propria before the therapy (p = 0.02; r = 0.5).
Conclusions. We suggest that modulation of vascular proliferation can be a novel option to increase the efficacy 
of biological therapy in CD. (Folia Histochemica et Cytobiologica 2016, Vol. 54, No. 2, 75–80)
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Introduction
Anti-tumour necrosis factor alpha (anti-TNF) therapy 
in Crohn’s disease (CD) modulates the pathological 
inflammatory processes in the gut wall, providing 
tissue repair and mucosal healing. However, direct 
mechanisms of these phenomena are not known [1]. 
Surprisingly, according to current data, it seems that 
the most important pathways induced by these novel, 
powerful and clinically effective drugs are not directly 
related to TNF neutralization [2, 3].
Immune-mediated angiogenesis in the intestinal 
tissues is believed to be one of the driving forces of 
inflammatory infiltrations and histological lesions in 
the gut in CD. On the other side, multiple pro-in-
flammatory mediators induced during inflammation 
promote pathological angiogenesis. Thus inflamma-
tion and angiogenesis seem to be directly interrelated 
processes in CD pathogenesis [4–7]. 
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The exact influence of anti-TNF antibodies on 
intestinal angiogenesis is still being investigated. It 
is not well known whether modulation of enhanced 
angiogenesis during therapy is associated with mi-
croscopic healing. It also remains to be elucidated 
which parameters of microscopic activity in CD can 
be hypothetically more closely related to the change 
in immune-mediated angiogenesis in patients treated 
with anti-TNF agents.
In the present study we measured the intensity of 
mucosal vessel proliferation by detecting the immuno-
cytochemical expression of CD31 (platelet endothe-
lial cell adhesion molecule — PECAM-1) in colonic 
biopsy specimens before and after anti-TNF therapy 
in CD patients. In parallel to that we also assessed 
the expression of vascular endothelial growth factor 
(VEGF) — the strongest angiogenesis-promoting 
protein, as well as the microscopic activity by using 
a validated histological score. 
The main aim of our study was to evaluate the 
influence of anti-TNF induction therapy in CD on 
the immune-mediated angiogenesis in relation to 
microscopic and endoscopic healing.
Material and methods
Patients. CD patients (12 females and 5 males, aged 32 ± 
10 years, mean ± standard deviation) treated with induction 
doses of anti-TNF antibodies, infliximab (IFX) or adali-
mumab (ADA) were enroled into the study. The study was 
approved by a local Ethics Committee and the informed 
consent was obtained from each patient.
Inclusion criteria were as follows: clinical exacerbation 
of CD not responding to maximal doses of standard ther-
apy (steroids, mesalamine, thiopurines), full colonoscopy 
performed before and after induction anti-TNF therapy, 
clinically successful application of induction anti-TNF 
therapy defined as a decrease in CDAI by 100 points, 
ileocolonic or colonic CD localization. Exclusion criterion 
was the change in the concomitant therapeutic regimen 
during the induction doses of anti-TNF agents and pri-
mary non-response to the therapy. Disease activity was 
assessed twice — before enrolment and at the end of the 
induction period of anti-TNF treatment, i.e. 10–12 weeks 
after starting the biological therapy. Clinical activity was 
estimated by using the Crohn’s Disease Activity Index 
(CDAI), endoscopic severity was graded according to the 
Simple Endoscopic Score for Crohn’s Disease (SES-CD) 
by an experienced endoscopist [8, 9]. During colonoscopy, 
multiple biopsies were taken for further analyses from 
each affected segment of the colon (caecum and ascending 
colon, transverse colon, descending colon, sigmoid colon 
and rectum, if appropriate). 
Tissue processing and the assessment of microscopic CD 
activity. All specimens were stained with haematoxylin and 
eosin (HE) and the microscopic activity was assessed by the 
validated score created by D’Haens et al. [10]. This score 
takes into account the most important features of histolog-
ical lesions detected in CD: epithelial damage (0–2 points), 
architectural changes (0–2 points), infiltration of mononu-
clear cells in the lamina propria (0–2 points), infiltration of 
polymorphonuclear cells in the lamina propria (0–3 points), 
presence of polymorphonuclear cells in epithelium (0–3 
points), presence of erosions and/or ulcers (0–1 points), 
presence of granulomas (0–1 points) and the number of 
biopsy specimens affected (0–3 points). The final score is 
the sum of all variables in specimens taken from all affected 
colonic segments divided by the number of segments. 
Immunohistochemistry and image analyses. Immunohisto-
chemistry has been carried out on representative sections 
using a Dako automated immunostainer (Dako Autostainer 
Link 48, AS 48430, Dako, Glostrup, Denmark) according 
to the manufacturer’s recommendations and standard pro-
tocols. Briefly, the paraffin embedded 4 μm-thick sections 
of formalin-fixed tissue samples were deparaffinised (PT-
-Link, Dako PT10530). Antigen retrieval (PT-Link, Dako 
PT10530) was performed using the Dako Target Retrieval 
Solution, High pH. Tissue sections were incubated with 
a mouse monoclonal antibody against VEGF (1:50; clone 
26503, R & D, Minneapolis, MN, USA) and with a mouse 
monoclonal antibody against CD31 (1:30; clone QBEnd 10, 
Dako). The EnVision Flex HRP (Dako) and EnVision Flex 
Substrate Buffer (Dako) were used for detection, employing 
3,3’-diaminobenzidine (DAB) as the chromogen. The sec-
tions were counterstained with haematoxylin and mounted. 
Positive control tissue with high vessels density (kidney) was 
used as recommended by the suppliers whereas exclusion of 
the primary antibody served as negative control. 
After immunostaining, all stained colonic sections were 
analysed. Two independent pathologists in a blinded manner 
counted all microvessels and cells positive for CD31 in the 
inflamed lamina propria in ten areas of most intense vas-
cularization (the ‘hot spots’) at ×400 total magnification. 
The mean values of the vessel count evaluated by CD31 
expression were calculated in every case as the arithmetic 
mean of ten counted areas. 
VEGF-positive cells were evaluated by the same pathol-
ogists in a blinded manner and the results were expressed 
using a semiquantitative score. The extent of VEGF stain-
ing was assessed as a percentage of positively stained areas 
(1: 0–20%; 2: 21–40%; 3: 41–75%, 4: 76–100%) within the tissue. 
VEGF staining intensity was graded as weak (1: +), moderate 
(2: ++) or strong (3: +++) using an arbitrary scale. By adding 
the percentage expression to the intensity of staining the 
staining index was calculated with values between 2 and 7.
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Statistical analysis. All data were analysed by the GraphPad 
Prism Version 6.0 program (GraphPad Software Inc., La 
Jolla, CA, USA) using non-parametric statistics for paired 
(Wilcoxon test) or unpaired (Mann-Whitney U test) data, 
as appropriate. Categorized data were assessed with the 
Fisher’s exact test. Correlations were assessed with the use 
of Spearman’s rank correlation coefficient. A p value < 0.05 
was considered significant. 
Results
Clinical, endoscopic, and biochemical  
activity of Crohn’s disease 
17 CD patients were included in the study (12 females 
and 5 males; age 32 ± 10 years, mean ± SD). The 
mean disease duration was 7 ± 5 years. The character-
istics of the study group in terms of clinical, endoscop-
ic, and biochemical activity before and after induction 
of anti-TNF therapy is shown in Table 1. Biological 
therapy resulted in a significant decrease of CD clin-
ical and endoscopic activity assessed by CDAI and 
SES-CD indexes, respectively. The sensitive inflam-
matory laboratory markers, like C-reactive protein 
(CRP), and erythrocyte sedimentation rate (ESR), 
fibrinogen, and platelets, also decreased significantly 
(Table 1). Although the total microscopic activity did 
not change, a detailed analysis of the score’s compo-
nents showed a significant decrease in the number 
of mononuclear- and polymorphonuclear cells in the 
mucosal lamina propria, as well as a decrease in the 
number of erosions/ulcers in biopsy specimens after 
the anti-TNF therapy (Table 1).
Table 1. Immunohistochemical expression of CD31 and Vascular Endothelial Growth Factor (VEGF) in colonic biopsies 
and selected biochemical, clinical and morphological parameters before and after anti-TNF therapy of Crohn’s disease 
patients
Before anti-TNF therapy After anti-TNF therapy P
CD31 (the mean number of CD31-positive microvessels  
in colonic lamina propria) 
24 (IQR: 21–29) 14 (IQR: 11–18) < 0.0001
VEGF (the final result is the sum of the percentage  
of positively stained areas and VEGF staining intensity  
in colonic lamina propria) 
5 (IQR: 4–6) 2 (IQR: 2–2) < 0.0001
CDa activity index 266 (IQR: 190–352) 63 (IQR: 37–129) < 0.0001
Simple Endoscopic Score for CDa 14  (IQR: 9–20) 4 (IQR: 3–5) 0.0005
C-reactive protein [mg/L] 31.27 ± 26.34 16.88 ± 23.57 0.001
ESRb [mm/h] 39 ± 19 20 ± 19 0.009
RBCc (106/mm3) 4.31 ± 0.69 4.13 ± 0.57 0.63
Haemoglobin [g/dL] 11.32 ± 2.31 11.62 ± 2.46 0.23
Haematocrit (%) 35 ± 6 35 ± 7 0.46
Platelets (103/mm3) 394 ± 116 323 ± 132 0.01
WBCd (103/mm3) 6.94 ± 2.68 5.94 ± 1.91 0.17
Fibrinogen [mg/dL] 514 ± 124 327 ± 150 0.003
Microscopic activity — D’Haens score (total) 6.33 ± 3.59 5.53 ± 4.19 0.34
Epithelial damage 0.41 ± 0.5 0.05 ± 0.1 0.1
Architectural changes 1.22 ± 0.9 0.9 ± 0.9 0.4
Mononuclear cells in LPe 1.63 ± 1.21 0.65 ± 0.81 0.03
Polymorphonuclear cells in LPe 2.44 ± 0.67 1.47 ± 1.32 0.01
Mono- and polymorphonuclear cells in LPe propria 4.04 ± 1.7 2.01 ± 2 0.006
Polymorphonuclear cells in epithelium 1.1 ± 0.82 0.8 ± 0.71 0.1
Erosions/ulcers 0.33 ± 0.41 None 0.01
Granulomas 0.09 ± 0.2 None 0.5
Number of biopsy specimens affected 2.61 ± 1.41 2.62 ± 1.65 0.5
Data are presented as medians with interquartile ranges (IQR) or mean ± standard deviation (SD). aCD — Crohn’s disease; bESR — erythrocyte 
sedimentation rate; cRBC — red blood cell count; dWBC — white blood cell count; eLP — lamina propria.
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Immunohistochemical expression of CD31  
and VEGF in mucosal biopsies
On immunohistochemistry CD31 expression was 
observed in all sections from inflamed colonic mu-
cosa, both before and after anti-TNF treatment. The 
anti-CD31 antibody selectively labelled endothelial 
cells and microvessels in the colon lamina propria 
(Figure 1A, C). On the contrary, VEGF was weakly 
expressed by vascular endothelium but intense VEGF 
immunoreactivity was present in the infiltrating in-
flammatory cells. VEGF was widely expressed in the 
lamina propria cells before anti-TNF therapy and only 
focally after the treatment (Figure 1B, D). Median 
immunoreactivity of both CD31 and VEGF in colonic 
specimens decreased significantly after finishing the 
induction phase of biological therapy. 
Significant correlation between the change in 
CD31 and VEGF immunoreactivity before and af-
ter anti-TNF treatment (delta CD31/delta VEGF: 
p = 0.01; r = 0.6) was found. The decrease in CD31 
expression was also significantly associated with the 
improvement in endoscopic activity (delta CD 31/ 
/delta SES-CD: p = 0.04; r = 0.4). We did not find, 
however, any direct correlations between CD31 and 
VEGF expression, and CD31 immunoreactivity and 
SES-CD score. 
Microscopic activity assessed globally did not 
correlate with neither CD31 nor VEGF immunoex-
pression, however, in case of CD31 expression and 
histological assessment before anti-TNF therapy the 
correlation was of a borderline significance (p = 0.06; 
r = 0.4). Analysis of the components of microscopic 
activity revealed that CD31 immunoreactivity was 
significantly associated with the number of poly- and 
mononuclear cells assessed together in the inflamma-
tory infiltrates in the mucosa before commencement 
of the anti-TNF therapy (p = 0.02; r = 0.5). 
Discussion
CD31 is a protein found mainly on endothelial cells 
(EC), platelets, monocytes and granulocytes [11]. It is 
believed that the intensity of CD31 expression reflects 
the degree of angiogenesis, especially in neoplastic 
tissues [11, 12]. In our study we confirmed that CD31 
is also highly expressed on EC in intestinal biopsies 
taken from inflamed mucosa of CD patients. This 
phenomenon correlated with a number of poly- and 
mononuclear cells in the inflammatory infiltrates in 
the mucosa. This suggests that angiogenesis is one of 
the driving forces of inflammation in CD, as the pres-
ence of numerous proliferating small vessels enables 
the migration of mononuclear cells from the intra-
vascular space to the intestinal tissue what promotes 
tissue inflammation and damage. This is in accordance 
with novel therapeutic strategies in inflammatory 
bowel diseases (IBD), in which the blockade of the 
aforementioned phenomena is believed to be one of 
the most powerful therapeutic options [13, 14]. In 
2014 vedolizumab, a monoclonal antibody blocking 
Figure 1. Immunohistochemical expression of CD31 and vascular endothelial growth factor (VEGF) before and after 
anti-tumour necrosis factor therapy in colonic biopsies from Crohn’s disease patients (CD31: A and C, VEGF: B and D, 
respectively). Sections were counterstained with haematoxylin. Original magnification ×400.
A B
C D
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the a4b7-integrin, was approved by the Food and 
Drug Administration. Vedolizumab interferes with 
the interaction between gut-selective a4b7-integrin on 
leukocytes and mucosal addressin cellular adhesion 
molecule-1 (MadCAM-1) on endothelial cells [15] 
what down-regulates the migration of leukocytes to 
the intestinal lamina propria and provides histological 
improvement [16]. 
Interestingly, VEGF expression did not correlate in 
our study group with that of CD31, although VEGF is 
believed to be one of the most potent pro-angiogenic 
factors [16–18]. In an active inflammatory milieu, 
however, there is an elevation of concentration of 
multiple pro-inflammatory cytokines, like TNF-a, 
interleukin-1 (IL-1), transforming growth factor beta 
(TGF-a), several other growth factors, and other 
mediators (like hypoxia inducible factor-1, HIF-1) 
which indirectly (via VEGF) or directly promote angio - 
genesis [16]. Thus, vessel proliferation in CD is stimu-
lated by a complicated network of several molecules, 
rather than by single proteins, although VEGF still plays 
a key role in angiogenesis. Moreover, our recent finding, 
showing that serum VEGF not only correlates with CD 
clinical activity, but also can be helpful in predicting the 
efficacy of anti-TNF therapy, supports morphological 
observations presented in this study [19].
Anti-TNF treatment rapidly dampens the activat-
ed and uncontrolled inflammatory processes in intes-
tinal mucosa in IBD [20]. One can hypothesize that 
down-regulation of immune-stimulated angiogenesis 
is essential for the therapeutic efficacy of biological 
therapy. To the best of our knowledge, we showed for 
one of the first times that in CD patients responding 
to the treatment there is a significant reduction of 
CD31-positive endothelial cells in biopsy specimens 
taken from inflamed colon mucosa. Thus, admin-
istration of the anti-TNF agent decreases mucosal 
vessel proliferation. Moreover, the change in CD31 
expression correlated with mucosal healing (MH) 
assessed endoscopically. This is important from the 
practical point of view, as it was shown that MH has 
the strongest positive predictive value for long-term 
efficacy of anti-TNF therapy [21]. Thus, it seems that 
down-regulation of immune-mediated angiogenesis is 
at least partially responsible for endoscopic improve-
ment and clinical effectiveness of biological therapy 
in CD. We also observed a significant decrease in 
VEGF expression after induction anti-TNF therapy, 
which correlated with a reduction in CD31 expression. 
Thus, although, as it was discussed above, CD31 and 
VEGF did not correlate before and after the treat-
ment, they were significantly associated when assessed 
dynamically in the course of biological therapy. It can 
be speculated that this observation is related to the 
involvement of both proteins in the same angiogene-
sis-regulating phenomena, which were influenced by 
anti-TNF antibodies.
Interestingly, although there was a significant 
decrease in CD31 and VEGF expression, the index 
of microscopic activity only slightly improved after 
anti-TNF therapy. It can be hypothesized, however, 
that down-regulation of angiogenesis in the colon 
mucosa is one of the first steps in histological healing 
in CD. As the inflammatory tissue lesions seen in CD 
are often chronic and very complex, it may take some 
time to obtain profound improvement also on the 
cellular and histological level [22].
As it was mentioned above, the reduction of 
vascular proliferation in CD is probably indirectly 
related to the decrease of several pro-inflammatory 
and pro-angiogenic mediators after administration of 
anti-TNF antibodies. Taking into account the impor-
tance of angiogenesis in the etiology of CD, it could be 
hypothesized that a more direct inhibition of vascular 
proliferation together with anti-inflammatory effects 
of anti-TNF agents, could improve therapeutic out-
comes. In accordance with this hypothesis, Kanakaraj 
et al. showed that application of a bispecific antibody, 
containing an angiopoietin-2 targeting peptide genet-
ically fused to adalimumab, the anti-TNF antibody, 
in transgenic mouse model of arthritis, reduced both 
clinical and histological scores significantly better 
when compared with adalimumab alone [23]. It is 
not possible to translate these observations directly 
into patients with CD; nevertheless, this approach 
may present a next step in therapeutic strategies of 
chronic inflammatory disorders in the future, after 
critical assessment of its safety and costs.
In summary, the current study showed that standard 
anti-TNF therapy has a strong potential to down-reg-
ulate angiogenesis in the intestinal mucosa of CD 
patients, when assessed on the histological level, 
which is accompanied with clinical and endoscopic 
improvement. As the vascular proliferation seems 
to be one of the important pathomechanisms for 
inflammatory activity of CD, it is essential to search 
for new drugs affecting these processes in order to 
improve the efficacy of therapeutic interventions in 
this incurable gastrointestinal disease.
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